IceCure Medical Ltd (ICCM)
| Market Cap | 19.08M -67.3% |
| Revenue (ttm) | 3.57M +8.9% |
| Net Income | -15.74M |
| EPS | -0.23 |
| Shares Out | 81.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 524,834 |
| Open | 0.2350 |
| Previous Close | 0.2357 |
| Day's Range | 0.2293 - 0.2425 |
| 52-Week Range | 0.2150 - 1.4000 |
| Beta | 1.63 |
| Analysts | Strong Buy |
| Price Target | 1.48 (+529.79%) |
| Earnings Date | May 12, 2026 |
About ICCM
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncolo... [Read more]
Financial Performance
In 2025, IceCure Medical's revenue was $3.38 million, an increase of 2.67% compared to the previous year's $3.29 million. Losses were -$15.06 million, -1.70% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ICCM stock is "Strong Buy." The 12-month stock price target is $1.48, which is an increase of 529.79% from the latest price.
News
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-f...
IceCure Medical price target lowered to $1 from $3 at Maxim
Maxim lowered the firm’s price target on IceCure Medical (ICCM) to $1 from $3 and keeps a Buy rating on the shares. The company’s Q1 loss per share was slightly…
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares CAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or th...
IceCure Medical reports Q1 EPS (6c) vs. (6c) last year
Reports Q1 revenue $911K, consensus $1.34M. “We are off to an incredibly strong start to 2026 and we are highly encouraged by the growing momentum we are experiencing in the…
IceCure Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 26% revenue growth year-over-year, with U.S. sales up 31% and active accounts rising 46% post-FDA clearance. Strong commercial momentum is expected to continue, supported by expanding reimbursement, new clinical studies, and global interest.
IceCure Medical Earnings release: Q1 2026
IceCure Medical released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance Acce...
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
CAESAREA, Israel, May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys...
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
As the only FDA cleared minimally invasive treatment option for low-risk breast cancer, ProSense® is aligned with the trend toward de-escalation of breast cancer treatment—a key theme at this year's m...
IceCure Medical initiated with a Buy at Alliance Global
Alliance Global analyst Scott Henry initiated coverage of IceCure Medical (ICCM) with a Buy rating and $1 price target IceCure is an Israel-based medical technology company developing and commercializ...
IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates Cryoablation cost analysis study from Massac...
IceCure Medical files to sell 16M ordinary share for holders
16:33 EDT IceCure Medical (ICCM) files to sell 16M ordinary share for holders
IceCure Medical Registration statement: Registration filing
IceCure Medical filed a registration statement on April 1, 2026, providing details about a securities offering with the SEC.
IceCure Medical announces $4M registered direct offering
IceCure Medical (ICCM) announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8M ordinary shares at a purchase p...
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
CAESAREA, Israel, March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure Medical reports results from clinical trial of ProSense for SRMs
IceCure Medical (ICCM) announced positive top-line results from its ICESECRET clinical trial of ProSense for the treatment of small renal masses, or SRMs, in kidney cancer patients. A total of…
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population Full analysis of resul...
IceCure Medical appoints Meir Peleg as CFO
IceCure Medical (ICCM) appointed Meir Peleg as its CFO, effective May 17. Meir Peleg combines a software engineering background with over 20 years of financial leadership, having previously served as…
IceCure Appoints Meir Peleg as Chief Financial Officer
Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies IceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24...
IceCure Medical Registration statement: Registration filing
IceCure Medical filed a registration statement on March 20, 2026, providing details about a securities offering with the SEC.
IceCure Medical Earnings Call Transcript: Q4 2025
Record 2025 revenue of $3.4M was driven by FDA clearance and new guidelines for ProSense, fueling strong U.S. and global adoption. Expansion into Canada and Japan, a 30-site post-marketing study, and reimbursement improvements are expected to accelerate growth.
IceCure Medical Earnings release: Q4 2025
IceCure Medical released its Q4 2025 earnings on March 17, 2026, summarizing the period's financial results.
IceCure Medical Annual report: Q4 2025
IceCure Medical has published its Q4 2025 annual report on March 17, 2026.
IceCure Medical reports FY25 EPS 24c vs 30c last year
Reports FY25 revenue $3.379M vs $3.291M last year. “2025 was a pivotal year for IceCure. Following the FDA’s clearance for cryoablation of low-risk breast cancer in October, we had record…
IceCure Reports 2025 Full Year Financial & Operational Results
Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectively Strong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cance...